Dynavax Technologies is focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation.

Dynavax GmbH (Dynavax Europe), is the European affiliate of Dynavax Technologies Corporation. For more than 25 years, we have been dedicated to the development and manufacturing of vaccines and …

Dynavax’s pipeline is focused on harnessing our CpG 1018 adjuvant as an advanced vaccine adjuvant to discover, develop, and commercialize promising vaccines to prevent infections diseases.

Dynavax wholly owns, manufactures and holds worldwide commercial rights to HEPLISAV-B. Bavarian Nordic markets and distributes HEPLISAV B in Germany with an expected launch mid-2022.

Nov 5, 2025 · Dynavax is a commercial-stage biopharmaceutical company built on the foundation of our significant experience and expertise in vaccine development and commercialization.

At Dynavax Technologies, we are developing cutting-edge vaccines based on Toll-like Receptor (TLR) biology and its ability to control and modulate the immune system.

Dynavax Technologies Corporation, 2100 Powell Street Suite 900, Emeryville, CA 94608

Aug 21, 2025 · It combines an antigen, glycoprotein E, with Dynavax's proprietary adjuvant system, CpG 1018, and alum and may help overcome the natural age-related decline in responses to …

Collaboration positioned to leverage Vaxart's oral vaccine platform and Dynavax's commercial experience to address the long-term need for easily administered COVID-19 vaccine options Vaxart …

Dynavax GmbH (Dynavax Europe), is the European affiliate of Dynavax Technologies Corporation. For more than 25 years, we have been dedicated to the development and manufacturing of vaccines and …